 |
|
|
|
 |
Phase I/II Study of Vandetanib with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
[Protocol 08-137]
- Full Title :
- PHASE I/II STUDY OF VANDETANIB WITH RADIATION THERAPY AND CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
- Purpose :
The standard treatment for glioblastomas and gliosarcomas is temozolomide (Temodar®) and radiation therapy. Research has shown that glioblastomas have genetic changes that may cause an excess of certain cell growth factors and their receptors, which can cause uncontrolled tumor growth.
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called vandetanib in patients newly diagnosed with glioblastoma or gliosarcoma when combined with radiation therapy and temozolomide. Vandetanib is designed to block receptors to two of these growth factors: vascular endothelial growth factor and epidermal growth factor.
Blocking these receptors may help slow tumor growth and reduce the blood supply to the tumor. Laboratory evidence also suggests that blocking these receptors may increase the sensitivity of glioblastomas to radiation therapy.
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have newly diagnosed glioblastoma or gliosarcoma that has not yet been treated with radiation therapy or chemotherapy.
- Biopsy or surgery to remove the tumor must have been completed within 4 weeks of entering the study.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Andrew Lassman at 212-639-6037.
|
|
|
|
|
